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Abstract
AIM: To assess the efficacy of intravenous cyclophos-
phamide pulse therapy for refractory infl ammatory bowel 
disease (IBD).
 
METHODS: We included in our cohort eight patients 
with (moderate/severe) steroid refractory IBD (4 with 
ulcerative colitis and 4 with Crohn’s disease). They all 
received 6 cycles of intravenous cyclophosphamide (800 
mg) per month. 
RESULTS: Patients entered into remission after the sec-
ond/third cyclophosphamide pulse. Disease activity de-
creased. There were no side effects and toxicity. All the 
patients went into long lasting remission. All Crohn’s disease 
patients and 3 of 4 ulcerative colitis patients achieved 
complete remission. One patient with ulcerative colitis 
showed an impressive clinical response but did not enter 
into remission. For the maintenance, patients with Crohn’s 
disease were treated with methotrexate (15 mg/wk) and 
patients with ulcerative colitis were treated with azathio-
prine (2.5 mg/kg body weight/d). 
CONCLUSION: Remission was maintained in all patients 
for 6 mo on the average. The drug was well tolerated. 
These fi ndings suggest that aggressive immunosuppres-
sive therapy may be useful in some refractory patients 
and further controlled study should be considered in or-
der to fully evaluate this type of treatment as a potential 
therapy for IBD.
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Crohn’s disease (CD) and ulcerat ive col i t is (UC), 
collectively referred to as inflammatory bowel disease 
(IBD), are relatively common inflammatory diseases 
of  the gastrointestinal (GI) tract. Histopathologically 
and anatomically, these two conditions are distinct, with 
CD characterized by transmural inflammation that can 
occur throughout the GI tract, and UC characterized 
by more superficial inflammation confined to the colon 
and rectum. The etiology and pathogenesis of  IBD are 
not yet completely understood. Although the details of  
the pathogenesis of  IBD remain elusive, it is believed 
that exposure of  genetically susceptible individuals to 
environmental factors (e.g., dietary antigens, luminal 
bacteria) seems to be an important factor for the 
development and chronicity. 
    Pharmacotherapy for IBD has essentially been 
unchanged for over twenty years, with therapy based on 
5-aminosalicylic acid (5-ASA) preparations, corticosteroids, 
antibiotics and immunosuppressants. Many of  the 
controversies about optimal use of  these drugs in IBD 
arise as a consequence of  methodological deficiencies 
in many of  the trials combined with the difficulty in 
consistent patient selection due to the heterogeneous 
nature of  both UC and CD. Current therapy for IBD 
is neither sufficient nor disease-modifying. The first-
line therapy for IBD fl ares is typically medical in nature. 
Long-term treatment with non-specifi c anti-infl ammatory 
drugs such as aminosalicylates, corticosteroids and 
immunosuppressants i s often accompanied with 
undes i rable and potent ia l ly ser ious s ide effects. 
Glucocorticoids are a mainstay for the treatment of  
severe inflammatory bowel disease. Aminosalicylates are 
efficacious in the treatment of  active mild to moderate 
disease. Infl iximab, a chimeric monoclonal anti-TNF alpha 
antibody can be used in treatment of  refractory Crohn’s 
disease[1]. Novel biologically-driven therapies are targeted 
to specific pathophysiological processes, offering the 
potential for better treatment outcomes. 
    The management of  refractory, severe IBD is yet 
an unsolved problem. Accurate assessment of  specific 
organ involvement and disease severity is vital if  we are 
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going to tailor appropriate therapy for certain patient. 
In common with other disease, the aims of  therapy 
for IBD fall into three categories, namely induction of  
remission, maintenance of  remission, and prevention of  
relapse. All should be undertaken with minimal mortality 
and morbidity either from the disease itself  or from the 
therapy 
    Cytotoxic drugs prevent cell division or cause cell death. 
They act predominantly on rapidly dividing cells such as 
T lymphocytes, and are therefore immunosuppressive and 
anti-infl ammatory. When cytotoxic drugs are initially used 
in the treatment of  cancer, they have profound effects 
on the immune system. This “unwanted” side effect has 
subsequently been exploited for the treatment of  non-
malignant disease where autoimmune mechanisms are 
considered important in the pathogenesis. Based on the 
previous observations of  improvement in autoimmune 
diseases (i .e. , vasculitides), cyclophosphamide can 
be the primary cytotoxic drug[2-4]. Pulse intravenous 
cyclophosphamide is probably equally effective as oral 
cyclophosphamide at inducing remission and this remission 
is usually maintained by continuing cyclophosphamide 
for 3-6 mo before changing to a combination of  other 
per os therapy. Cyclophosphamide can be administered 
intravenously at 500-1000 mg/m2 pulses monthly. 
The optimal duration of  treatment with intravenous 
cyclophosphamide has not been determined for IBD, but 
treatment for six months with monthly pulses would be 
typical, followed by maintenance therapy with azathioprine 
or methotrexate. Therapy must be continued to prevent 
relapse and for maintenance. 
    Only sporadic but promising cases are reported and 
experiences with cyclophosphamide in severe IBD are very 
limited but most patients entering into remission have no 
major adverse events or side effects[5]. We here report some 
other cases to enrich the experiences.  We designed a non-
controlled prospective pilot study to investigate the effects 
of  pulse cyclophosphamide therapy for IBD patients. The 
aim of  this study was to examine the effect of  this kind of  
therapy on UC and CD. 
MATERIALS AND METHODS
Patient selection and treatment
All patients were recruited in this prospective uncontrolled 
pilot study from our out-patient clinic specializing in 
chronic inflammatory bowel diseases (at the 3rd Depart-
ment of  Medicine, University of  Debrecen). Between 
September 2002 and December 2003 we included in our 
cohort eight patients with (moderate/severe) steroid re-
fractory IBD (four patients with CD and four with UC).   
    All patients were diagnosed according to the standard 
criteria and underwent endoscopy and/or radiological 
studies, including ileo-colonoscopy, CT and/or double-
contrast barium air enteroclysis during 6 mo of  the study. 
Video endoscopy of  the large intestine, including the ter-
minal ileum, was performed before the fi rst cyclophospha-
mide pulse and at wk 12. All the patients did not respond 
to conventional therapy (this was the only selection criteria 
for this study) and were treated with pulse cyclophos-
phamide therapy monthly (6 cycles). The bolus dose was 
applied independent of  body weight. Cyclophosphamide 
(800 mg) was given during a 4 h hospital stay in 500 mL 
physiologic or normal saline (0.9%) in a period of  120 
min. White blood cell (WBC) counts and urine tests for 
incidental microscopic haematuria were obtained on pre- 
and post-cyclophosphamide therapy day (0, 7, 14). 
Dutcome measurement
All the patients were informed of  the potential risks and 
benefits of  cyclophosphamide therapy and a written in-
formed consent was given in advance. We defi ned treat-
ment failure as any of  the followings: lack of  an initial 
response, relapse after an initial response, and intolerance 
to cyclophosphamide necessitating discontinuation of  the 
drug. We used the modified Truelove and Witts activity 
index for ulcerative colitis and best index (Crohn’s disease 
activity index) for Crohn’s disease as others[6,7]. We used 
working definitions for the assessment of  the response 
both in UC and CD. Active disease was defi ned as symp-
tomatic UC with a Truelove-Witts score greater than 6 
points and symptomatic CD with a CDAI score greater 
than 150 points. Signifi cant (moderate-severe) relapse was 
defi ned as symptomatic UC with a Truelove-Witts score 
greater than 10 points and symptomatic CD with a CDAI 
score greater than 150 points and/or the need for systemic 
steroid therapy (including oral budesonide), and treatment 
failure was defi ned as relapse, colectomy or any serious ad-
verse event. 
RESULTS
Patient histories are summarized in Table 1. CD patients 
were all females aged 36-65 years (mean 49 years) and UC 
patients were all males aged 29-59 years (mean 40.25 years).
Each patient received six monthly treatment. All patients 
were continued on a daily regimen of  methyl prednisolone 
and the daily dose was decreased according to individual 
clinical activity. Azathioprine (2.5 mg/kg body weight per 
day) and methotrexate (15 mg/wk) were initiated orally 
for UC and CD patients respectively to maintain remission 
following cyclophosphamide treatment.  
    The patients entered into remission after the second/
third cyclophosphamide pulse. Disease activity decreased. 
There were no side effects and no toxicity. All the patients 
went into long lasting remission. Remission seemed stable 
(except for case 5: relapse after 6 mo). These findings 
suggested that aggressive immunosuppressive therapy 
might be useful in some refractory patients and further 
controlled study should be considered in order to fully 
evaluate this type of  treatment as a potential therapy for IBD. 
DISCUSSION
Current therapy for IBD is unsolved. Many drugs are 
prescribed for inflammatory bowel disease, either for 
treating active disease or for maintaining remission. 
However, no drug provides a completely satisfactory 
response in a large percentage of  patients. Corticosteroids 
(steroids) at dosages equivalent to 40-60 mg/d prednisone 
are commonly prescribed for acute exacerbations of  
Crohn’s disease and ulcerative colitis. Steroids are not 
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effective for maintenance of  remission in either disease. 
However, some patients require long-term steroids for 
suppression of  disease, particularly Crohn’s disease. Taking 
steroids for a prolonged period can cause reversible or 
irreversible adverse effects[8-10]. These adverse effects are of  
suffi cient concern to prompt consideration of  alternative 
treatment strategies. Infl iximab, human growth hormone, 
and other novel biotechnology treatments have been 
investigated as therapy for patients with inflammatory 
bowel disease. Although these biotechnology-derived 
treatments are promising, their cost is prohibitive for many 
patients. Because cyclophosphamide is effective for other 
inflammatory conditions and is relatively less expensive 
than some other agents, it is considered in the treatment 
of  infl ammatory bowel disease.
    IBD continues to pose a challenge to clinicians. Over 
the past few years there have been significant advances 
in our understanding of  its pathogenesis and treatment. 
These advances may lead to more specific and targeted 
treatments, with consequent improvements in clinical 
outcomes. Intravenous pulse cyclophosphamide therapy 
may be a safe and effective treatment for patients with 
severe IBD unresponsive to conventional treatment 
as a first-line adjunct to or replacement of  systemic 
corticosteroids in the treatment of  IBD. Last but not the 
least, costs of  this kind of  treatment are relatively low. 
    In conclusion, pulse cyclophosphamide therapy can 
be used in treatment of  selected IBD patients. However, 
larger placebo-controlled studies in more diverse patient 
population are warranted.
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1 46/female CD 26 colon-rectum 168/79 methotrexate
2 65/female CD 18 ileum-colon-rectum 231/86 methotrexate
3 49/female CD 22 ileum-colon 198/91 methotrexate
4 36/female CD 5 ileum-colon 242/98 methotrexate
5 59/male UC 5 rectum 14/6 azathioprine
6 44/male UC 5 rectum 15/8 azathioprine
7 29/male UC 4 recto-sigmoid 13/6 azathioprine
8 29/male UC 8 recto-sigmoid 14/7 azathioprine
UC-DAI: Modifi ed Truelove and Witts activity index for UC; CDAI: CD activity index; Methotrexate: 15 mg/wk; Azathioprine: 2.5 mg/kg body weight per day.
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